A DNA-targeted hypoxic cell radiosensitizer and
cytotoxin, 5-[3-(2-nitro-1-imidazoyl)-propyl]-
phenanthridinium bromide (2-NLP-3), has been shown previously to have increased efficacy over untargeted analogues in vitro. To further study the mechanism of action of this compound, a cell line, CHO-1000, derived from Chinese hamster ovary (CHO) AA8-4 cells was isolated. This cell line is capable of continuously growing in a concentration of
2-NLP-3 approximately 10-fold greater than that tolerated by wild-type CHO cells. The resistance of CHO-1000 to
2-NLP-3 was compared with that of the
P-glycoprotein overexpressing, multidrug resistant Chinese hamster cell line CHR-C5 (C5). The resistance of CHO-1000 cells to the acute toxic effects of
2-NLP-3 under both hypoxic and aerobic exposure conditions was intermediate to that of the sensitive CHO wild-type cells and the resistant C5 cells. A similar pattern was seen for the hypoxic cell radiosensitizing ability of
2-NLP-3.
2-NLP-3 produced significant depletion of
glutathione under both hypoxic and aerobic conditions in all three cell lines studied, and the degree of depletion was correlated with
drug toxicity. CHO-1000 and C5 cells were significantly more resistant to
colchicine and
doxorubicin compared with wild-type cells. The toxicity pattern of
2-NLP-3 and its comparison
phenanthridinium ion, P3, was not the same for CHO-1000 cells compared with C5 cells.
Verapamil was an effective agent for reversing the hypoxic resistance to
2-NLP-3 in both CHO-1000 and C5 cells, but only a partial reversal of aerobic resistance was observed in CHO-1000 cells. These results indicate that the resistant phenotype of CHO-1000 is mediated to some degree by
P-glycoprotein expression, but that other as yet unidentified factors are also involved.